Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures.
The periprocedural management of patients with atherosclerotic coronary heart disease, including those who have heart disease and those who are undergoing percutaneous coronary intervention and stent placement who might require temporary interruption of platelet-directed pharmacotherapy for the purpose of an elective endoscopic gastrointestinal procedure, is a common clinical scenario in daily practice. Herein, we summarize the available information that can be employed for making management decisions and provide general guidance for risk assessment.
Becker
Richard C
RC
Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27705, USA. becke021@mc.duke.edu
Scheiman
James
J
Dauerman
Harold L
HL
Spencer
Frederick
F
Rao
Sunil
S
Sabatine
Marc
M
Johnson
David A
DA
Chan
Frances
F
Abraham
Neena S
NS
Quigley
Eamonn M M
EM
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000818:Animals; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000628:therapy; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D016099:Endoscopy, Gastrointestinal / Q000009:adverse effects; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000517:prevention & control; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D012308:Risk Management; D015607:Stents / Q000009:adverse effects; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods*
D010975:Platelet Aggregation Inhibitors